NCT00089193View on ClinicalTrials.gov

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

September 30, 2003

Primary Completion Date

February 28, 2007

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

multi-epitope melanoma peptide vaccine

BIOLOGICAL

sargramostim

Trial Locations (5)

15232

Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh

20010

Washington Cancer Institute at Washington Hospital Center, Washington D.C.

22908

Cancer Center at the University of Virginia, Charlottesville

19111-2497

Fox Chase Cancer Center, Philadelphia

77030-4009

MD Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Craig L Slingluff, Jr

OTHER

NCT00089193 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | Biotech Hunter | Biotech Hunter